POPULARITY
Categories
64 episodes with phase ii
17 episodes with phase ii
19 episodes with phase ii
13 episodes with phase ii
13 episodes with phase ii
15 episodes with phase ii
13 episodes with phase ii
6 episodes with phase ii
10 episodes with phase ii
7 episodes with phase ii
6 episodes with phase ii
9 episodes with phase ii
6 episodes with phase ii
12 episodes with phase ii
6 episodes with phase ii
3 episodes with phase ii
5 episodes with phase ii
6 episodes with phase ii
5 episodes with phase ii
5 episodes with phase ii
2 episodes with phase ii
4 episodes with phase ii
5 episodes with phase ii
18 episodes with phase ii
9 episodes with phase ii
6 episodes with phase ii
5 episodes with phase ii
5 episodes with phase ii
9 episodes with phase ii
7 episodes with phase ii
3 episodes with phase ii
3 episodes with phase ii
4 episodes with phase ii
2 episodes with phase ii
4 episodes with phase ii
7 episodes with phase ii
4 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
6 episodes with phase ii
7 episodes with phase ii
3 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
4 episodes with phase ii
51 episodes with phase ii
3 episodes with phase ii
2 episodes with phase ii
3 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
2 episodes with phase ii
Century Lithium CEO Bill Willoughby joined Steve Darling from Proactive to announce the results of an updated NI 43-101 compliant Feasibility Study for the company's 100%-owned Angel Island Lithium Project in Nevada. The 2026 Feasibility Study incorporates additional metallurgical testing, engineering optimization, refinement of the mine plan, and updated capital and operating cost estimates. The updated analysis demonstrates strong project economics, highlighted by an after-tax net present value (NPV) of $4.01 billion. Importantly, no material changes were made to the Mineral Resource or Mineral Reserve estimates referenced in the prior NI 43-101 Technical Report. Willoughby explained that the 2026 study reconfigures Angel Island into a streamlined two-phase development plan. Phase I envisions a 7,500 tonnes-per-day (tpd) operation, followed by an expansion to 15,000 tpd in Phase II. The third expansion phase contemplated in the 2024 study has been removed, simplifying project execution and significantly reducing overall upfront capital requirements. Under the updated model, the after-tax NPV of $4.01 billion is based on price assumptions of $24,000 per tonne for lithium carbonate and $750 per dry metric tonne for sodium hydroxide. The project is positioned as a large, long-life U.S.-based lithium development, with Proven and Probable Reserves supporting a mine life exceeding 60 years. Capital requirements have been substantially reduced. Phase I initial capital costs are now estimated at $997 million, down from $1.537 billion in the 2024 study. Phase II expansion capital is projected at $660 million, compared to $651 million previously. Operating efficiencies have also improved, with average operating costs estimated at $22.45 per tonne of mill feed, equivalent to $4,389 per tonne of lithium carbonate — a significant reduction from $8,223 per tonne outlined in the prior study. Century Lithium plans to continue advancing Angel Island toward development through submission of its plan of operations, ongoing permitting efforts, detailed engineering work, and engagement with potential strategic and financial partners as the project moves toward a construction decision. #proactiveinvestors #centurylithiumcorp #tsxv #lce #otcqx #cydvf #mining #AngelIsland #LithiumProject #NevadaMining #FeasibilityStudy #NI43101 #LithiumCarbonate #BatteryMaterials #EnergyTransition #USMining #CriticalMinerals #MineDevelopment #NPV #LongLifeAsset #EVSupplyChain #StrategicMetals #ProjectFinance #ResourceDevelopment
Discover how to lose weight without Ozempic using 5 evidence-backed strategies. This episode breaks down why insulin resistance is the real driver of weight gain and how cutting processed foods, eating only when hungry, fasting, weight resistance training, and detoxification can help you lose weight naturally and sustain it long-term — no prescription required. FEATURED PRODUCT The Good Poops Protocol is designed to support the exact systems discussed in this episode — liver detoxification, gut health, and blood sugar regulation.
We’re starting our read of Cavan Scott’s Path of Vengeance, the final novel in Phase II of the High Republic. We talk about ghosts, unraveling the Mother’s identity, and what Marda Ro has been up to (spoiler alert: it’s cult shit). For a list of Black-owned bookstores to order from, now and always, click here. […]
NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce the filing of the company's financial results for the quarter ended December 31, along with a corporate update highlighting progress on its lead antiviral candidate, NV-387. Dr. Diwan said the company is advancing NV-387—a novel broad-spectrum antiviral that represents a new class of antiviral drugs—toward a Phase II clinical trial. NanoViricides is preparing to initiate a Phase II human study to evaluate the safety and effectiveness of NV-387 as a treatment for MPox in the Democratic Republic of Congo (DRC). The local regulatory authority, ACOREP, has already approved the Phase II clinical trial, subject to the completion of certain remaining requirements. The company reported that most of these conditions have been satisfied and is now focused on final site readiness and documentation necessary to formally launch the trial. Management stated that current funding is sufficient to execute and complete the planned Phase II study in the DRC according to its projections. In parallel, NanoViricides has filed an application for Orphan Drug Designation for “NV-387 as a Treatment for MPox” with the U.S. Food and Drug Administration Office of Orphan Products Development. If granted, orphan designation would provide incentives including tax credits for qualified clinical trial expenses, exemption from certain regulatory user fees, and the potential for seven years of market exclusivity following regulatory approval. MPox is caused by infection with the MPXV virus, an orthopoxvirus. Currently, there is no drug specifically approved for the treatment of MPox. NV-387 has demonstrated strong antiviral effectiveness in a mouse model of dermal lethal infection using ectromelia virus, an orthopoxvirus closely related to the viruses responsible for smallpox and MPox. The company also noted that NV-387 has successfully completed a Phase I human clinical trial, demonstrating safety and tolerability in healthy adults with no reported adverse events. Based on these results and preclinical efficacy data, NanoViricides believes NV-387 represents a promising clinical candidate for the treatment of MPox as it advances into mid-stage human trials. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #nanoviricides #NV387 #OrphanDrugDesignation #AntiviralTherapy #ClinicalTrials #PhaseII #OrphanDrugDesignation #FDA #DrugDevelopment #InfectiousDisease #BiotechInnovation #GlobalHealth #Orthopoxvirus #BroadSpectrumAntiviral #PharmaUpdate #EmergingDiseases #HealthcareInnovation #ClinicalResearch
Send a textWhy do some scientific breakthroughs begin with ridicule?In this episode, we explore cancer research, serendipity, and the philosophy behind unconventional biomedical innovation.Dr. Alexander Shneider, Ph.D. is a biotech entrepreneur and scientist with more than three decades of experience spanning oncology, immunology, vaccines, and translational medicine. He is the Founder and CEO of CureLab Oncology ( https://www.curelaboncology.com/ ), where he is leading the development of a novel biological agent designed to fight cancer through a dual approach—stimulating anti-tumor immunity while also addressing the chronic inflammation that often underlies disease progression.CureLab's lead therapeutic, Elenagen, has demonstrated a strong safety profile and encouraging signals of clinical benefit in international Phase II studies, and is being explored both as an adjunct to standard cancer treatments and for its broader potential in inflammation-driven and age-associated diseases. The platform's reach may extend beyond human medicine, with ongoing interest in applications for oncology in companion animals.Over the course of his career, Dr. Shneider has advised biotechnology, pharmaceutical, and investment organizations across areas including R&D strategy, licensing, technology transfer, product development, and intellectual property. He previously founded CureLab, Inc., where he worked on tools for the rational design of DNA vaccines and the development of broad-spectrum influenza vaccine concepts.In academia, Dr. Shneider has held professor-level appointments and led the Genetic Vaccine Laboratory at Sechenov University, where he helped establish multicenter clinical research infrastructure focused on diseases involving chronic inflammation. His research has also explored evolutionarily conserved RNA structures as targets for antiviral therapies and next-generation vaccine design.In addition to his scientific and entrepreneurial work, he serves on the editorial boards of several peer-reviewed journals in immunology and aging research, reflecting his long-standing engagement at the intersection of basic science, clinical translation, and biotechnology innovation.#CancerResearch #BiomedicalScience #CancerInnovation#ScientificDiscovery #PhilosophyOfScience #Biotech #MedicalInnovation#Oncology #BreakthroughScience #StartupScience #SciencePodcast #DrugDevelopment #Serendipity #Innovation #FutureOfMedicineSupport the show
What if one of the most powerful tools for detoxification, brain health, hormone balance, and healthy aging was something you could grow in your kitchen? In this science-packed episode of The Girlfriend Doctor Podcast, Dr. Anna Cabeca sits down with renowned nutritional biochemist Dr. Jed W. Fahey — the pioneering researcher behind the discovery of the extraordinary chemoprotective power of broccoli sprouts. After 27 years at Johns Hopkins University School of Medicine, where he directed the Cullman Chemoprotection Center, Dr. Fahey explains why sulforaphane — derived from glucoraphanin found abundantly in broccoli sprouts — activates your body's own protective systems at the cellular level. Dr. Anna shares her personal clinical experiences using sulforaphane-rich compounds to support detoxification pathways, immune resilience, abnormal Pap smears, skin health, neurocognitive protection, and hormone balance — especially in midlife women. In this episode, you'll learn: What sulforaphane actually is (and why it matters) How it activates phase II detoxification pathways Why broccoli sprouts are more potent than mature broccoli Neuroprotective and brain benefits Research around skin and melanoma protection Dosage guidance for sprouts vs. supplements How to safely incorporate them into your daily routine This isn't about trendy superfoods. It's about turning on your body's built-in defense systems. Small daily choices. Powerful cellular protection. Key Timestamps 00:01 – Welcome & why broccoli sprouts matter 03:14 – Broccoli sprouts vs. mature broccoli: what's the difference? 06:21 – What exactly is sulforaphane? 09:24 – Phase II detoxification explained simply 15:23 – Dr. Anna's powerful clinical case using sulforaphane 17:31 – Brain health & neurocognitive benefits 24:43 – How much should you take daily? 31:24 – Skin health & melanoma research 33:35 – Food vs. supplement: dosage considerations 42:13 – One big takeaway for healthy aging Memorable Quotes "This isn't about complicated science. It's about small daily choices that protect your cells." "Sulforaphane switches on your body's own protective systems." "Broccoli sprouts are foundational — not optional — for longevity." "We want to help and do no harm." "You were made for vitality." Connect With Our Guest Dr. Jed W. Fahey
What if one of the most powerful tools for detoxification, brain health, hormone balance, and healthy aging was something you could grow in your kitchen? In this science-packed episode of The Girlfriend Doctor Podcast, Dr. Anna Cabeca sits down with renowned nutritional biochemist Dr. Jed W. Fahey — the pioneering researcher behind the discovery of the extraordinary chemoprotective power of broccoli sprouts. After 27 years at Johns Hopkins University School of Medicine, where he directed the Cullman Chemoprotection Center, Dr. Fahey explains why sulforaphane — derived from glucoraphanin found abundantly in broccoli sprouts — activates your body's own protective systems at the cellular level. Dr. Anna shares her personal clinical experiences using sulforaphane-rich compounds to support detoxification pathways, immune resilience, abnormal Pap smears, skin health, neurocognitive protection, and hormone balance — especially in midlife women. In this episode, you'll learn: What sulforaphane actually is (and why it matters) How it activates phase II detoxification pathways Why broccoli sprouts are more potent than mature broccoli Neuroprotective and brain benefits Research around skin and melanoma protection Dosage guidance for sprouts vs. supplements How to safely incorporate them into your daily routine This isn't about trendy superfoods. It's about turning on your body's built-in defense systems. Small daily choices. Powerful cellular protection. Key Timestamps 00:01 – Welcome & why broccoli sprouts matter 03:14 – Broccoli sprouts vs. mature broccoli: what's the difference? 06:21 – What exactly is sulforaphane? 09:24 – Phase II detoxification explained simply 15:23 – Dr. Anna's powerful clinical case using sulforaphane 17:31 – Brain health & neurocognitive benefits 24:43 – How much should you take daily? 31:24 – Skin health & melanoma research 33:35 – Food vs. supplement: dosage considerations 42:13 – One big takeaway for healthy aging Memorable Quotes "This isn't about complicated science. It's about small daily choices that protect your cells." "Sulforaphane switches on your body's own protective systems." "Broccoli sprouts are foundational — not optional — for longevity." "We want to help and do no harm." "You were made for vitality." Connect With Our Guest Dr. Jed W. Fahey
On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Chief Policy Officer Michael Koplow and Distinguished RAND Israel Policy Chair Shira Efron. The trio discuss this week's summit meeting in Washington between President Trump and Prime Minister Netanyahu, the chances of negotiations with Iran actually succeeding, the likely gaps between the U.S. and Israel over any potential deal, the threat of a military attack if diplomacy fails, how Phase II in Gaza is going, the recent damaging steps taken by the Israeli government on the West Bank, and more.Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.
Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company's second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company's lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is now progressing through a 50:50 co-development partnership with Sequel Med Tech. The collaboration is preparing for a pivotal phase two clinical study, which Arecor is targeting to begin in the second half of 2026. She noted that both teams share a vision of combining next-generation automated insulin delivery (AID) systems with next-generation insulin to improve patient outcomes and reduce disease management burden. Positive negotiations are also underway regarding a broader co-development and commercialisation partnership. On the oral GLP-1 programme, Howell highlighted the challenge of bioavailability, pointing out that Rybelsus (semaglutide), an oral GLP-1 tablet for adults with type 2 diabetes, currently achieves “less than 1% oral bioavailability.” Arecor is conducting nonclinical pharmacokinetic studies aimed at improving bioavailability, which could be highly translatable across multiple peptide therapeutics. Financially, the company reported unaudited revenues of £3.1 million for 2025 and cash of £6.1 million at year-end, extending the runway into the first half of 2027. For more insights into Arecor Therapeutics PLC's strategy and upcoming milestones, visit Proactive's YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates. #ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors
On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber and Israel Policy Forum Director of Strategic Initiatives and IPF Atid Shanie Reichman discuss the state of play in the Iran crisis, potential upcoming U.S.-Iran talks and the prospects for their success, Ran Gvili z”l's return home last week and the closure of the hostage saga, the real start of Phase II in the Gaza ceasefire and the mechanics behind it, Zohran Mamdani and the Jewish community one month in, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.
Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. These numbers appear to put CT-388, which Roche acquired in its $2.7 billion Carmot buy, in line with Eli Lilly's Zepbound, according to William Blair analysts. Roche plans to start a Phase III study of CT-388 in the first half of this year and is also pairing the drug with a therapy from Zealand Pharma, with the aim of offering a weight lossoption with fewer gastrointestinal side effects. Meanwhile, Baseline Therapeutics debuted to challenge Lilly with a Phase III–ready GLP-1 for alcohol use disorder. In the vaccines sector, Moderna took perhaps the biggest action to date amid Health Secretary Robert F. Kennedy's anti-vaccine policies and rhetoric, last week announcing that the company will no longer run late-stage vaccine trials for infectious diseases. “You cannot make a return on investment if you don't have access to the U.S. market,” CEO Stéphane Bancel saidthe World Economic Forum at Davos, Switzerland. Pfizer CEO Albert Bourla, also speaking at Davos, called RFK Jr.'s rhetoric and policies on vaccines “anti-science.” Finally, Sarepta released new data on Monday for Elevidys, the company's embattled gene therapy for neuromuscular disease Duchenne muscular dystrophy. Plus, check out up-and-coming treatments for Alzheimer's and Parkinson's.
What will Phase II of Trump's plan for Gaza look like on the ground? Who's in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing structure — Trump's “Board of Peace,” the Gaza Executive Committee, a Palestinian technocrat government, and an International Stability Force — and explain what will actually matter on the ground: money, security control, and whether Hamas truly disarms. They also assess Israel–U.S. friction, the odds of renewed fighting, what daily life in Gaza looks like right now, and how all of this collides with Israeli election politics.In this episode...- Understanding the Governance of Gaza- Who Holds Power in Gaza? Money, Security, and Accountability- Hamas After the War- Phase Two, the Yellow Line, and Israeli Withdrawal- The International Stability Force Explained- Life in Gaza Right Now- Gaza Meets Israeli Politics- The Bigger Regional PictureFrom the episode:This episode was sponsored by The Shalom Hartman Institute: Learn more about the Community Leadership Program at https://go.hartman.org.il/CLP-CMBMore Ark Media:Want to join Ark Media? Check out our careers page for new openings.Subscribe to Inside Call me BackListen to For Heaven's SakeListen to What's Your Number?Watch Call me Back on YouTubeNewsletters | Ark Media | Amit Segal | Nadav EyalInstagram | Ark Media | DanX | DanDan Senor & Saul Singer's book, The Genius of IsraelGet in touchCredits: Ilan Benatar, Adaam James Levin-Areddy, Brittany Cohen, Martin Huergo, Mariangeles Burgos, and Patricio Spadavecchia, Yuval Semo
What will Phase II of Trump's plan for Gaza look like on the ground? Who's in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing […]
Roche/Genentech announced on June 15–16, 2025 that prasinezumab — an anti-α-synuclein monoclonal antibody — will enter Phase III trials for early Parkinson's disease after mixed but encouraging Phase II signals. In this episode (watch on YouTube) we explain the biology behind α-synuclein targeting, summarize the PASADENA and PADOVA findings (what was missed and what looked promising), discuss safety issues and trial design challenges, and speak with experts/patients about realistic timelines and hopes for disease-modifying therapies To follow trials like this and to have customized information and results delivered to you directly, consider signing up to try Turnto and the AI sidekick Turny. Sign up here and use the promo code PDEDUCATION for a 10% discount: https://www.turnto.ai/sidekick?fpr=pdeducation Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join https://www.patreon.com/pdeducation Please be sure to give support to our channel sponsors: Comfort Linen: https://comfortlinen.com/PARKINSONSDISEASEEDUCATION(15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes: https://kizik.sjv.io/pdeducation Cure Hydration: https://lvnta.com/lv_XG06Rho8SSlXEq3qlV If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer All information, content, and material of this video is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use. #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsons #prasinezumab #monoclonalantibodies #alphasynuclein
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson's disease and outlines Phase II plans for the company's lead asset HER-096.
Listen below or click here for full show notes Star Trek’s Robert Picardo Pens Strong Message About Franchise’s History Ahead Of Starfleet Academy Robert Picardo Reminds Fans What STAR TREK Has Always Been as The Franchise Turns 60 — GeekTyrant Zoe Saldaña Becomes Highest-Grossing Actor of All Time With ‘Avatar 3’ Main Mission, Part 1 (with an appropriate sound effect) Star Trek: Starfleet AcademySeason 1, episode 1“Kids These Days”Written by Gaia VioloDirected by Alex Kurtzman Subspace Chatter Star Trek panoramas from the CD-ROM era – Boing Boing Exclusive: Christina Chong Talks “More Swings” For ‘Strange New Worlds' Season 4, “Bittersweet” Season 5 – TrekMovie.com Say Goodbye to Star Trek on Netflix Star Trek Fans Bought A Lot Of Props At Auctions In 2025, But I’m Shocked At The Most Expensive Get From The Next Generation Alex Kurtzman on Star Trek's Future — and Paramount's New Regime ‘Star Trek: Strange New Worlds’ Casts Sulu and Bones for Series Finale STAR TREK: STRANGE NEW WORLDS Series Finale Casts Thomas Jane as McCoy, Kai Murakami as Sulu – TrekCore.com Dr. McCoy and Mr. Sulu to Appear in Star Trek: Strange New Worlds Series Finale – IGN ‘Star Trek’ Legend Offered ‘Klingon School’ to 2026 Cast Warner Bros. Discovery Still Sounds Open to a Paramount Deal DOJ Reviewing Paramount’s Warner Bros. Discovery Bid Paramount Loses Bid to Fast Track WBD Disclosures on Netflix Deal Paramount Loses Bid to Fast Track WBD Disclosures on Netflix Deal In Vulcan, Alberta, Canada news… Town of Vulcan Recreation – Public Access Here are links to 144 additional stories.broken out by series, movies and other categories. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] Star Trek: TOS S2 episodes to be thankful for on Turkey Day One Star Trek Actor Played Three Characters in the Original Series (After She Was Cut From The Pilot) Star Trek actress, 85, makes unexpected comments about co-star William Shatner | HELLO! Star Trek Used Kissing Noises To Create The Sound Of A Classic Monster Star Trek episode showed Trekkies just how funny the series could be 59 Years Later, This Star Trek: TOS Episode Remains the Scariest Hour in Sci-Fi TV History One Line From Star Trek: The Original Series Created A 58-Year Plot Hole The Star Trek spinoff Starfleet Academy is as much a school on-screen as it is off, according to co-star George Hawkins | Popverse Classic Star Trek Is Finding A New Audience Through YouTube Reaction Videos – TrekMovie.com One of Kirk’s Greatest ‘Star Trek’ Episodes Ever Is a Masterclass in 1 Thing the Sci-Fi Show Does Best One Star Trek Actor Couldn’t Do Spock’s Vulcan Salute Star Trek’s Tribbles Got Their Noise From A Very Unlikely Animal Star Trek: The Next Generation (1987 – 1994) [7 seasons] Star Trek: The Next Generation’s “Schisms” Is Still the Darkest Hour of Body Horror in Trek History Star Trek’s annoying TNG guests shouldn't stop fans from watching must-see Data episode “I can’t, they’re out of control”: Denise Crosby on Star Trek Director Getting Fed Up of TNG Cast Star Trek: TNG Is Superior Because It Respected One Rule The Original Series Constantly Broke All 7 Seasons of STAR TREK: TNG, Ranked 32.9M Streaming Hours Prove This ‘Star Trek' Spin-Off Aged Better Than Expected The Star Trek: The Next Generation Episode That Michael Dorn Considers The Worst Star Trek: The 7 Best Captain Picard Episodes Of All Time – ComicBook.com New Star Trek Show Finally Completes The Redemption Of The Next Generation’s Most Hated Character – ComicBook.com 6 Darkest Star Trek: The Next Generation Episodes, Ranked Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] 28 Years Ago, Star Trek's Future Was Changed Forever in 2 Weeks Star Trek: Voyager (1995 – 2001) [7 seasons] Star Trek’s Controversial Janeway Episode Is the Most Problematic 46 Minutes in Sci-Fi History Star Trek: Voyager’s Best, Darkest Story Was Almost A Season-Long Adventure – ComicBook.com Star Trek: Enterprise (2001 – 2005) [4 seasons] The Worst ‘Star Trek' Episode Ever Pointlessly Killed Off a Beloved Character To “Create Conversation” STREAMING SERIES AND MOVIES (in order of premiere) Star trek: Prodigy (2021 – 2024) [2 seasons] Star Trek's Most Beloved Show Being Erased From Streaming In 2026, You Can’t Watch It | GIANT FREAKIN ROBOT Kate Mulgrew Reacts to ‘Star Trek: Prodigy’ Cancellation Star Trek: Strange New Worlds (2022 – present) [4th season yet to premier, 5th/final season finished filming] Star Trek: Strange New Worlds: Christina Chong Wraps Series Filming Star Trek: Strange New Worlds’ Christina Chong Shared A Post After Wrapping On The Final Season, And I’m Starting To Get Emotional | Cinemablend A Star Trek: Strange New Worlds Director Shared The Last Time The Cast Was On The Bridge, And I Have Two Big Questions | Cinemablend Star Trek actor can’t even find the words as Strange New Worlds wraps “Star Trek: Strange New Worlds” Cast & Crew Say Farewell STAR TREK: STRANGE NEW WORLDS Wraps Production; Cast Bids Farewell with Two Seasons Yet to Air – TrekCore.com Melissa Navia teases deeper trauma and untold backstory for Strange New Worlds pilot Erica Ortegas | Popverse Star Trek legacy villain could show up in Strange New Worlds finale (and this is how) Star Trek: Section 31 (streaming TV event) Star Trek: Section 31' Nominated For Image Award – TrekMovie.com Star Trek: Starfleet Academy [2026 – present] [renewed for second season] Paul Giamatti, Star Trek's Latest Villain, Just Proved His Trek Fandom to Us – IGN First Look: Wrestling Champion Becky Lynch On The ‘Star Trek: Starfleet Academy' Bridge – TrekMovie.com Star Trek’s Next Villain Is Channeling 4 of The Most Iconic Sci-Fi Bad Guys Of All Time – ComicBook.com Meet the Cadets of STAR TREK: STARFLEET ACADEMY in Video Spotlights, Plus Behind-the-Scenes Peeks at Production – TrekCore.com Set primarily on Earth, Star Trek: Starfleet Academy rethinks what a Star Trek series can be | Popverse Alex Kurtzman Explains Why Starfleet Academy Isn't Set Post-‘Picard,' Hints More Star Trek TV Is In Development – TrekMovie.com Star Trek Fans Clash Over Klingons as One Actor Responds – Parade Star Trek Star Hits Back At New Show’s Klingon Controversy – ComicBook.com 25 Years Later, New Star Trek Show Finally Fixes A Major Voyager Injustice – ComicBook.com Every Legacy Star Trek Character We Hope to See in Starfleet Academy ‘Most-Hated’ Character Honored in New ‘Starfleet Academy’ Clip – Parade Star Trek’s Next Series Is Breaking A Cardinal Rule Of Every Show So Far – ComicBook.com Star Trek: Starfleet Academy’s Karim Diane Knows His Klingon Character Is Different, But Explains Why It’s Not Uncommon | Cinemablend | Cinemablend Star Trek: Starfleet Academy — Season 1 review: ‘compelling’ Starfleet Academy Will Revive an Age-Old Star Trek Conundrum | Den of Geek ‘Star Trek: Starfleet Academy’: Paul Giamatti and Holly Hunter on beaming into the storied sci-fi franchise (interview) | Space Star Trek: Starfleet Academy – A Love Letter To Deep Space Nine In Episode 5 See New STAR TREK: STARFLEET ACADEMY Photos from This Week's Two-Episode Premiere, “Kids These Days” and “Beta Test” – TrekCore.com New Star Trek Spinoff Has an Unexpected Alien: Romulus Connection (Exclusive) Holly Hunter Says ‘Star Trek’ Role Is like ‘Winning the Lottery' Star Trek’s New Spinoff Officially Explores a Canon-Accurate Detail About Klingon Healers (Exclusive) Star Trek Confirmed The Return of a One Off Villain to Live-Action – ComicBook.com PREVIEW: Star Trek: Starfleet Academy Series Premiere – Trek Central Paul Giamatti On Villain in Big Fat Liar, Star Trek Starfleet Academy Holly Hunter & Paul Giamatti on ‘Star Trek: Starfleet Academy,’ Villains & Federation Legacy – YouTube Star Trek: The Burn profoundly affects Starfleet Academy Star Trek: Starfleet Academy's American Museum of Natural History premiere – downthetubes.net Star Trek: Starfleet Academy Review: Star Trek Meets College Drama in This Fun but Frustrating Series – TV Guide Star Trek: Starfleet Academy – Boldly Going Nowhere, But So Very Youthfully — Original Cin Star Trek: Starfleet Academy Review: A Playful New Spinoff Star Trek Starfleet Academy Review, Season 1 On Paramount Plus TV Review: What grade does STAR TREK: STARFLEET ACADEMY deserve? Starfleet Academy review: Star Trek kicks off 60th anniversary by connecting its past and future Star Trek: Starfleet Academy review – The kids are alright ‘Starfleet Academy’ Is a Solid Successor to the ‘Star Trek’ Legacy Early Review: ‘Starfleet Academy' Season 1 Deftly Balances Strong Characters, Star Trek Lore, And Different Tones – TrekMovie.com Star Trek: Starfleet Academy Brings Historic Firsts For The Franchise Star Trek is placing new show Starfleet Academy in an uncertain future to make it more meaningful for new fans today | Popverse ‘Star Trek: Starfleet Academy’ Brings Back What Fans Have Been Missing Star Trek Starfleet Academy TV Review: An introduction to the next generation of the franchise Star Trek Is About To Ruin Your Favorite Voyager Character Paul Giamatti Ranks His Favorite Star Trek Shows and Talks Star Trek: Starfleet Academy – YouTube Star Trek actor provides BTS tour of Starfleet Academy Exclusive: ‘Starfleet Academy' Showrunners Talk Easter Eggs, DS9 “Love Letter,” And Keeping Star Trek Alive – TrekMovie.com Exclusive: Robert Picardo And Gina Yashere On Ad Libbing & Season 2 Of ‘Star Trek: Starfleet Academy' – TrekMovie.com unannounced “Captain Janeway” series Star Trek: Kate Mulgrew on Janeway Spinoff Series Becoming a Reality unannounced “Resort Planet” series [currently in early development] “Star Trek” Comedy Series Update – Dark Horizons Trek series that never were, for one reason or another, [such as “Phase II”] 19 Lost ‘Star Trek’ Episodes From the Unproduced ‘Phase II’ Series | Woman’s World THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: The Motion Picture (1979) William Shatner Said Star Trek: The Motion Picture’s Uniforms Threatened His ‘Ability To Procreate’ Star Trek II: The Wrath of Khan (1982) The Star Trek Actor Who Spoiled Spock’s Death Before Wrath Of Khan Even Began Shooting Star Trek VI: The Undiscovered Country (1989) 20 Things You Never Knew About Star Trek VI: The Undiscovered Country – video Dailymotion OTHER MEDIAStar Trek books, audio books Star Trek: Khan: Beyer Discusses Starfleet Academy, Canon Flexibility Star Trek collectibles Review — Fanhome's New USS Archer and USS Harlan Expand the STAR TREK Starship Collection – TrekCore.com EXO-6 Reveals New STAR TREK: STRANGE NEW WORLDS Captains Chair Replica with Authentic Lights and Sounds – TrekCore.com Star Trek DVDs Star Trek: SNW season 3 warp-speeds beyond digital (epic SteelBook on the horizon) Star Trek video games/board games Embracer sell Neverwinter and Star Trek Online devs Cryptic, allowing them to gather their party and boldly go where Saber went before | Rock Paper Shotgun Embracer Group sells publisher Arc Games and Star Trek Online developer Cryptic Studios, but once again clings on to the publishing rights for Remnant 2 | PC Gamer ICv2: New ‘Star Trek: Into the Unknown’ Release Features Cardassians and Klingons A Look Into ‘Star Trek: Star Realms – Borg: Invasion Expansion' Destination Board Game: Star Trek: The Next Generation– Master Replicas Master Replicas Unveils Three Star Trek XL Desk Mats Inspired by Iconic Bridge Stations – GameSpace.com “Star Trek: Voyager – Across the Unknown” Release Date & Switch 2 Confirmed; Watch New Gameplay Video – TrekMovie.com Star Trek Comics/graphic novels/magazines See Janeway Fight To Escape The Clutches Of Species 8472 In Preview Of ‘Star Trek: Voyager: Homecoming' #3 – TrekMovie.com The Resurrected Captain Kirk Takes Command in Star Trek: The Last Starship #3 – IGN The Wild STAR TREK: TNG ’80s Comic Had a Space Santa – Nerdist Star Trek Can’t Let Captain Kirk Go, And It’s Become A Problem Star Trek Celebrates 60th Anniversary with Webtoon Expansion in 2026 IDW Preview: Star Trek: Strange New Worlds: Seeds Of Salvation #5 | Comic Book Club In Review: Star Trek: Voyager—Homecoming #4 – Between A Rock and A Hard Place See Spock Befriend A Giant Space Squid In ‘Star Trek: Strange New Worlds: The Seeds of Salvation' #5 Preview – TrekMovie.com MISCELLANEOUS Franchise-wide/Miscellaneous 12 Philosophical Star Trek Episodes That Will Leave You Thinking It's Hard To Be Excited About ‘Starfleet Academy' When the Star Trek Franchise Is Struggling Netflix Says Goodbye to All Remaining Star Trek Titles From TOS to Strange New Worlds: How Long Will It Reasonably Take To Complete All Star Trek Episodes – Your Complete 2026 Guide A Brief History of Klingon-Federation Conflict 10 Best Holodeck Episodes In Star Trek, Ranked The life and legacy of Dr. Soong, the creator of Star Trek’s DataWhat To Expect From Star Trek In 2026: A Franchise At A Crossroads – TrekMovie.com Star Trek 2025: The Biggest News And Surprises Of The Year 10 Star Trek Episodes That Predicted The Future Star Trek’s Renaissance During Stranger Things’ 9-Year Run The Star Trek Movie Timeline, Explained Star Trek’s most fascinating moments of 2025 ranked worst to first ‘To boldly go where no-one has gone before’ – opinion – Western People 12 Strongest Star Trek Characters, Ranked By Power 10 Greatest Star Trek Moments In 2025 Star Trek’s best Captain Christopher Pike actors ranked Star Trek: Everything We NOW Know About The 25th Century – YouTube Star Trek Showrunner Accidentally Admits How Boomers Saved The Franchise | GIANT FREAKIN ROBOT Star Trek: 10 Times Captains Lost Control – video Dailymotion 10 Biggest Reveals In Star Trek Novels – video Dailymotion 10 Deleted Star Trek Scenes That Would Have Changed Everything Star Trek Franchise Head Alex Kurtzman Gave Us An Update On His Contract And How He Feels About His Future | Cinemablend Paramount+ Holds ‘Star Trek: Starfleet Academy' World Premiere Event – Media Play News STAR TREK: STARFLEET ACADEMY Starts Soft Before Hitting Warp Speed (Review) – Nerdist STAR TREK: STARFLEET ACADEMY's First Class Has a Promising Start — Our Spoiler-Free Review – TrekCore.com Star Trek’s Allegory-First Storytelling Rule is Fumbled by Most Franchises 5 Star Trek Characters That Were Nerfed Over Time Trekkies, Michael Westmore’s documentary trailer looks out of this world UPDATE: Star Trek NOT Eligible For New Emmy Legacy Award… Due To A Technicality – TrekMovie.com Hear Me Out: I Think Hallmark Should Make A Holiday Movie For Star Trek Fans | Cinemablend What Is To Be Done About Star Trek? | Comic Book Club Actor Watch Jeri Ryan’s Favorite Star Trek Episode Is A Classic Original Series Adventure Tig Notaro: ‘Star Trek: Starfleet Academy’ shows ‘same Tig, different galaxy’ | Out.com ‘Star Trek' Icon, 94, Announces Nostalgic Event — and Fans Are Thrilled Star Trek’s Michael Dorn Questioned The Direction Of One Klingon Design William Shatner Connects ‘Star Trek,’ ‘Twilight Zone’ and Wizard of Oz (Exclusive) | Woman’s World How Rebecca Romijn Became a ‘Star Trek' Legend on ‘Strange New Worlds’ | Woman’s World Main Mission, Part 2 (with an appropriate sound effect) Star Trek: Starfleet AcademySeason 1, episode 2“Beta Test”Written by Noga Landau & Jane MaggsDirected by Alex Kurtzman End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Don’t put on the red shirt!
Due diligence is where real estate investors protect capital.In this episode of Commercial Real Estate Now, we break down how Phase I Environmental Site Assessments and Property Condition Assessments actually influence underwriting, financing, and long-term asset performance.You will learn:• How to interpret Recognized Environmental Conditions• When Phase I findings escalate to a Phase II inspection• Where PCA reports most often understate future capital requirements• How physical condition influences reserves, hold strategy, and risk profile This is a practical discussion for investors who want fewer surprises between acquisition and exit.Learn more about EBI Consulting: https://ebiconsulting.com/For speaking inquiries, collaboration, or investment discussions, contact Karly Iacono at karly.iacono@cbre.com or (201) 600-3237#RetailRealEstate #CommercialRealEstate #CREInvesting #RetailInsights #NetLease #RetailStrategy #EBIConsulting #duediligence #InvestmentInsights #RealEstateInvesting #KarlyIacono #commercialrealestatenow Warning-IRS Circular 230 Disclosure: CBRE and its affiliates do not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein is not intended or written to be used, and cannot be used, by the recipient of any Information for the purpose of avoiding U.S. tax-related penalties; and was written to support the promotion or marketing of the transaction or other matters addressed herein. Accordingly, any recipient of this video should seek advice based on your particular circumstances from an independent tax advisor. You also agree that the information herein down not constitute legal or other professional advice and you should obtain legal advice from a qualified attorney licensed in your state. The opinions contained in this video are those of Karly Iacono and may not represent those of CBRE. All content is for educational purposes only. The following content may contain the trade names or trademarks of various third parties, and if so, any such use is solely for illustrative purposes only. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and CBRE or Karly Iacono.
Tinnitus isn't just a ringing in your ears — it can interfere with memory, mood, and sleep, affecting your overall well-being when left unmanaged A Phase II clinical trial found that low-intensity sound therapy (LINTS) can reduce tinnitus symptoms without blocking out real-world sounds, helping the brain tune out the ringing naturally Sound therapy works by helping your brain reclassify tinnitus as background noise, reducing its emotional and cognitive impact over time For best results, work with a professional — sound therapy is most effective when guided by a trained audiologist Supporting your body with antioxidant-rich foods, magnesium, deep sleep, and a low-stress lifestyle can also reduce tinnitus intensity and help protect your hearing
On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Col. (ret.) Dr. Michael Milshtein, former head of the Department for Palestinian Affairs in Israel's Military Intelligence Directorate. They discuss the current status of the Gaza ceasefire deal, the contrasting realities on the ground in the Hamas-controlled red zone and the Israeli-controlled green zone, prospects for the U.S.-led Phase II of the deal, the upcoming meeting between Prime Minister Netanyahu and President Trump, fear of escalation in Lebanon, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.
At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations. First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study (NCT05396885) assessing treatment with anitocabtagene autoleucel (anito-cel) among patients with relapsed/refractory multiple myeloma. According to Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, the novel cellular therapy elicited an overall response rate (ORR) of 96% and a stringent complete response or CR rate of 74% among the evaluable patients. She also discussed how anito-cel's unique mechanism of action may show efficiency compared with other cellular therapy products while reducing the risk of cytokine release syndrome and other delayed toxicities. Next, Manali Kamdar, MD, spoke about data from a long-term follow-up phase 2/3 study (NCT03435796) based on the phase 3 TRANSFORM trial (NCT03575351) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) vs standard-of-care therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long-term follow-up showed that liso-cel continued to elicit improvements in progression-free survival and overall survival across this population. Kamdar, the clinical director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, touched upon the patient subpopulations who are most suitable to receive liso-cel while emphasizing the agent's curative potential in the second-line setting. Finally, Wei Ying Jen, BM BCh, MA, MMed, MRCP, FRCPath, detailed results from the phase 1/2 SAVE trial (NCT05360160), which showed responses with an all-oral combination of revumenib (Revuforj), decitabine/cedazuridine (Inqovi), and venetoclax (Venclexta) for patients with newly diagnosed acute myeloid leukemia. Jen, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, noted how an all-oral regimen may offer an “advantage” compared with standard intensive chemotherapy, which requires patients to travel to the hospital to undergo an infusion. References Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: updated results from iMMagine-1. Blood. 2025;146(suppl 1):256. doi:10.1182/blood-2025-256 Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. 2025;146(suppl 1):3710. doi.10.1182/blood-2025-3710 Jen WY, DiNardo CD, Short NJ, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(suppl 1):47. doi:10.1182/blood-2025-47
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcomaOsteosarcoma Webinar Series: Katie Janeway, MD and Suzanne Forrest, MD join us on OsteoBites to discuss results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.Dr. Janeway received her MD and MMSc from Harvard Medical School. She completed her pediatrics residency and her Pediatric Hematology-Oncology fellowship at Boston Children's Hospital and Dana-Farber Cancer Institute. She is an Associate Professor of Pediatrics, a Senior Physician who cares for young people with sarcoma, and Director of Clinical Genomics. Dr. Janeway's research is focused on precision oncology and bone sarcomas. She leads clinical trials both as an independent investigator and as the Chair of the Children's Oncology Group (COG) Bone Tumor Committee. The Janeway Laboratory leads several studies, which have enrolled and sequenced more than 2,500 patients with childhood cancers. They are using this data to deepen the understanding of clinical and genomic factors explaining prognosis and treatment response, and resistance, with a focus on sarcomas. In collaboration with Count Me In, the group is innovating patient partnerships in sarcoma research.Dr. Forrest completed her medical school training at Yale University, followed by pediatrics training in the Boston Combined Residency Program. She then pursued a pediatric oncology fellowship at Dana-Farber Cancer Institute / Boston Children's Hospital. Currently, she serves as an Assistant Professor of Pediatrics at Harvard Medical School and an Attending Physician in the Department of Hematology/Oncology at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Her research focuses on developing novel clinical trials that utilize cancer genomics to guide treatment strategies for pediatric solid tumors.After a short presentation on this research, they will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.
Today Pastor Stan explains how Phase II of the Gaza War COULD be the rise of the Third Beast. 00:00 Intro 01:27 Gang of Eight 05:50 Third Beast 14:31 Fourth Beast 15:05 Mark of the Beast
Today Pastor Stan explains how Phase II of the Gaza War COULD be the rise of the Third Beast. 00:00 Intro 01:27 Gang of Eight 05:50 Third Beast 14:31 Fourth Beast 15:05 Mark of the Beast
The US Senate Commerce Committee has voted to advance the nomination of Jared Isaacman to lead NASA. The Soyuz MS-27 crew has returned to Earth. Muon Space has been awarded a $1.9 million Small Business Innovation Research (SBIR) Direct to Phase II contract by SpaceWERX, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Dr. Michelle Hailey, Director of Global Affairs at Solamed Solutions. You can connect with Michelle on LinkedIn, and learn more about Solamed on their website. Selected Reading US Senate Committee votes to advance NASA nominee Jared Isaacman- Reuters NASA Astronaut Jonny Kim, Crewmates Return from Space Station Muon Space Secures Direct to Phase II Award Supporting Space Development Agency's Missile Warning and Tracking Mission Space Infrastructure Startup Mantis Space Selects Albuquerque for Headquarters and Manufacturing Hub Balerion Space Ventures Announces Strategic Investments in Three Companies Building the Infrastructure for America's Next Industrial Revolution In First, Wheelchair User Set To Go To Space - Disability Scoop Blue Origin Announces Crew for New Shepard's 37th Mission Share your feedback. What do you think about T-Minus Space Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices
OASIS+ enters Phase II with five new service domains and draft scorecards expected December 16 ahead of a January 12 solicitation date. The expansion could reshape competition and compliance for federal contractors, especially small businesses. Stephanie Kostro, President of the Professional Services Council is here to share her insights.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Drug resistance derails even the most advanced cancer treatments, but what if we could restore sensitivity to existing therapies instead of starting over? Neil Bhowmick, chief scientific officer at Kairos Pharma, joins In Vivo to discuss how his company is tackling resistance in oncology. We explore the company's lead asset, ENV-105, which is showing over 13 months of progression-free survival in Phase II prostate cancer trials by resensitizing tumors to hormone therapy, with significantly lower toxicity than standard alternatives like chemotherapy or radiopharmaceuticals. Bhowmick explains the complex biology behind different resistance mechanisms, shares early data on GITR-modulating therapies designed to expand T cell populations for immunotherapy, and discusses their approach to developing companion biomarkers for patient selection. We also dive into the clinical and commercial rationale for combination approaches and what milestones to watch in the coming year.
THIS VOYAGE, MARK A. ALTMAN (Pandora, The Librarians, 50 Year Mission), DAREN DOCHTERMAN (associate producer, STAR TREK: THE MOTION PICTURE) & ASHLEY E. MILLER (writer, Thor, X-Men: First Class) celebrate the 46th anniversary of STAR TREK: THE MOTION PICTURE as we are joined by associate producer JON POVILL, Epsilon 9 casualty MICHELE BILLY POVILL, publicist EDDIE EGAN, The Walking Dead showrunner and creative director SCOTT GIMPLE and Alien Boy himself, BILLY VAN ZADNT, whose been with the podcast every minute of her refitting. This is how we definite unwarranted! Join the Treksperts and special guests as we trace the development of Phase II's "In Thy Image" into the epic motion picture released December 7, 1979.**DON'T MISS THE TREKSPERTS AT GALAXYCON COLUMBUS 12/5 - 12/7 FOR MORE INFORMATION, GO TO GALAXYCON.COM ****TREKSPERTS+ SUBSCRIBERS NOW GET COMMERCIAL FREE EPISODES ONE WEEK EARLY! SUBSCRIBE TODAY AT TREKSPERTSPLUS.COM****Join us on our new INGLORIOUS TREKSPERTS DISCORD Channel at: https://discord.gg/7kgmJSExehRate and follow us on social media at:Blue Sky: @inglorioustrekspertsTwitter/X:@inglorioustrekFacebook:facebook.com/inglorioustrekspertsInstagram/Threads: @inglorioustrekspertsLearn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook and at @inglorioustreksperts on Instagram and Blue Sky. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed."Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times
Mining Stock Daily discusses the recent surge in the silver market and its impact on Argenta Silver, led by CEO Joaquin Marias. The discussion covers the company's new discovery at the Andrea Exploration Target, data-driven exploration strategies, and insights into the El Quevar South area. Marias emphasizes the importance of systematic exploration and the imminent results from their drilling program, highlighting the potential for significant silver and other mineral discoveries.
Novo Nordisk's highly anticipated data for semaglutide in Alzheimer's dashed hopes that the GLP-1 therapy could become a game changer in the disease. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses the Phase III readout including what it says about the mechanism's use in the neurodegenerative disease, Novo's decision to skip Phase II and enroll a large patient group in a later stage trial, and what other datasets for GLP-1s in the indication have shown.Washington Editor Steve Usdin explains why FDA's new vaccine policies, driven by CBER Director Vinay Prasad, could have impacts more far-reaching than expected, including making it more difficult to develop or modify vaccines. And Lauren Martz, Executive Director of Biopharma Intelligence, analyzes the bleak investment outlook for cell and gene therapy companies in the U.S. and why China's biotech ecosystem offers a glimmer of hope for sponsors of these assets.View full story: https://www.biocentury.com/article/657721#Semaglutide #GLP1Therapies #VaccinePolicy #CellAndGeneTherapy #AlzheimersResearch00:00 - Introduction01:53 - Novo's Alzheimer's Miss13:19 - FDA's New Vaccine Policy19:53 - Funding C> BiotechsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Audio roundup of selected biopharma industry content from Scrip over the business week ended November 28, 2025. In this episode: 2027 Medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J's Alzheimer's asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas's Padcev's first big win in bladder cancer study. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-R4RCDF2RXVGVHPEX2WQ7A3JVKU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example raising concerns that the agency is shifting the regulatory goalposts amid a lack of transparency. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin explains how the absence of advisory committee meetings at FDA is in part to blame for a lack of consistency in decision-making and divergence from decisions taken by other global regulatory agencies. VP and Editor-in-Chief Simone Fishburn then discusses the takeaways from Franck Le Deu's guest commentary on how China's biotech ecosystem is evolving, and whether government support for the sector is helping or hindering its overall health. BioCentury's analysts also discuss whether conventional CRISPR therapies will ever be commercially successful, and what's next for NLRP3 inhibitors to treat obesity following the first set of Phase II data for the class.We'd also like to invite our listeners to participate in our important survey about their experiences interacting with FDA. To take the survey, please go to BioCentury's FDA Sentiment Survey. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657698#FDARegulation #CRISPRTherapies #NLRP3Inhibitors #ChinaBiotech #DrugApproval00:01 - Sponsor Message: Voyager Therapeutics01:31 - FDA Sydnexis CRL07:36 - CDC Vaccine Claims09:55 - China's Innovation Arc16:49 - CRISPR Commercial Viability 26:39 - NLRP3 for ObesityTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Kiran Patankar is the recently appointed CEO of Maple Gold Mines and he joined MSD to close out our coverage of the DGM in Frankfurt. Kiran shares some insights on renewing exploration activities at the Douay Gold project and the Joutel Gold Project. He talks about bringing new institutions and investors into the story to re-emerge the projects into the forefront of the investment community. Since the interview, the company did announce a 30,000m Phase II drill program.
Delta Resources Chairman, Frank Candido, joined the pod for an update on the continued Phase II drilling program from the Delta-1 Project in Ontario. The company has been conducting big step-out drilling to define potential size and scale of the system. The program will include a minimum of 13 drill holes totaling over 3,100 metres, designed to expand the Eureka Gold Deposit and test satellite targets.
Our good friends, Mike and JT from Brew Crime, join us for November's unsolved crossover. Today, JT tells us about a terrifying six-year murder spree (1990-1996) targeted at least thirteen vulnerable elderly women in Richmond's West End, creating widespread panic. The case was officially pinned on one killer, but the narrative quickly fell apart: the series was split by a two-year hiatus and featured a pronounced shift from the stabbing homicides of six Black women to the homicides of seven White women. The case was hastily "closed" for the Phase II victims through the highly disputed confession of a diagnosed schizophrenic with zero forensic links to the crime scenes, leaving the initial wave of brutal stabbings completely unresolved. The official resolution is rooted in systemic failure and alleged racial bias, ensuring the actual killer, or killers, walked free. Source for the Episode Associated Press. (1996, April 25). Pattern Sought in Richmond Killings. The Roanoke Times. https://scholar.lib.vt.edu/VA-news/ROA-Times/issues/1996/rt9604/960425/04250042.htm Cases Solved Using Forensic Genetic Genealogy: How DNA Profiles Crack Cold Cases. (n.d.). Genomelink. Retrieved November 3, 2025, from https://genomelink.io/blog/cases-solved-using-forensic-genetic-genealogy-how-dna-profiles-crack-cold-cases Leslie Burchart. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Leslie_Burchart Perpetrator typologies and behavioral patterns in strangulation homicides: A Smallest Space Analysis. (n.d.). PMC. Retrieved November 3, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12046104 The Golden Years Murders. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Golden_Years_Murders https://richmondstandard.com/richmond/2025/02/26/richmond-city-council-honors-black-nine-guardians-of-justice/ Learn more about your ad choices. Visit megaphone.fm/adchoices
We’re starting our read of Lydia Kang’s High Republic novel, Cataclysm. This time, we’re discussing how Phase II characters have been affected by war, tension between the Republic government and the Jedi Order, and why Yaddle > Yoda. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe […]
On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Dan Shapiro, former U.S. ambassador to Israel. They discuss the method and timing behind the Trump-brokered Gaza ceasefire deal, comparisons with the Biden administration's diplomacy, whether senior U.S. officials are really coming to Israel to "Bibi-sit,” the prospects for Phase I of the deal holding, the challenges looming in Phase II, whether more regional normalization is really at hand, what's next on the Iran front, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.
This week on the Mark Levin Show, On Monday's Mark Levin Show, 7 million old hippies turned out in the Democrat-Marxist-Islamist No Kings mini-parades on Saturday? Well, 330 million Americans did not. The tea party movements had massive rallies, and it wasn't just one day. How is this President a king? He's working through the courts when he's blocked on improving America. For example, in a victory for America the 9th Circuit court ruled that the National Guard can be deployed in Portland. Also, Democrats turned a continuing resolution into a government shutdown blackmail threat to reverse provisions of the big, beautiful bill. Later, Marxist-Islamist Zohran Mamdani is pro-terrorism - from his associations with Imam Siraj Wahaj, his support for Hamas, his calls to globalize the Intifada, and his ties to the Qatar royal family. If people in NYC vote for Mamdani, they are voting for somebody who embraces terrorists, terrorist organizations, and hence, by implication, terrorism. Mamdani is no moderate, he's a grave threat to the people in New York City. Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy, and massive government spending to control the people. Later, Zohran Mamdani got his butt kicked at the NYC debate. He's a sloganeer, which is typical of Marxists, but he won't be substantive at all. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Featuring an interview with Dr Kevin Kalinsky, including the following topics: Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17) Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09) Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511. OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56) Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract CME information and select publications
China's major goals for the next five years include achievements in deepening reform and strengthening national security, as the country marches toward socialist modernization (01:15). China continues to share opportunities from its opening up at Phase II of the Canton Fair, and ahead of the China International Import Expo (14:10). Trade delegations from China and the United States will begin talks in Malaysia on Friday (31:38).
On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics: All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00) Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21) First- and second-generation IDH inhibitors for AML (17:40) Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59) Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42) Novel combination approaches with menin inhibitors for AML (29:11) CME information and select publications
THIS VOYAGE, MARK A. ALTMAN (Pandora, The Librarians, 50 Year Mission), DAREN DOCHTERMAN (associate producer, STAR TREK: THE MOTION PICTURE) & ASHLEY E. MILLER (writer, Thor, X-Men: First Class) welcome the team behind the ill-fated STAR TREK TV series, STAR TREK: PHASE II, to discuss the greatest "What If?" in all Trek history featuring story editor JON POVILL, Vulcan science officer, Xon, DAVID GAUTREAUX and assistant to the producers MICHELE BILLY POVILL as they spill the secrets on another TREK NOT TAKEN. DON'T MISS THE TREKSPERTS AT GALAXYCON ST. LOUIS, MILWAUKEE & COLUMBUS THIS FALL! FOR MORE INFORMATION, GO TO GALAXYCON.COM. **TREKSPERTS+ SUBSCRIBERS NOW GET COMMERCIAL FREE EPISODES ONE WEEK EARLY! SUBSCRIBE TODAY AT TREKSPERTSPLUS.COM****Join us on our new INGLORIOUS TREKSPERTS DISCORD Channel at: https://discord.gg/7kgmJSExehRate and follow us on social media at:Blue Sky: @inglorioustrekspertsTwitter/X:@inglorioustrekFacebook:facebook.com/inglorioustrekspertsInstagram/Threads: @inglorioustrekspertsLearn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook and at @inglorioustreksperts on Instagram and Blue Sky. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed."Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times
Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture China is now in talks again with the US, their plan has failed. Big Antimony refinery is being setup in Alaska, Trump is countering China every step of the way. Bessent warns the longer the shutdown goes it could hurt the economy, this is what the [CB] are trying to do. Investments are pouring into the US. Trump now has the [DS] where he wants them. They called in facist/Hitler and it has failed, he ushered in peace around the world and now when he has peace with Ukraine and Russia they will have a very difficult time pushing these names. The FBI has dismantled the largest human trafficking network. Trump is letting the people know that Phase II of the plan is now on track. Obama is struggling he looks defeated, by the time this is over he will try to escape to Kenya and the D party will cease to exist. Economy (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/KobeissiLetter/status/1977907063893225928 New: Alaska Scores Big on Antimony Refinery Antimony (Sb on the periodic table) is a strategic mineral with many applications. Shooters will recognize it, as it is frequently allied with lead to make a harder, more durable alloy for cast bullets. We should note that lead-antimony alloys have many other uses, from lead-acid batteries to sailboat keels. Antimony is used in other alloys as well, such as antifriction alloys, electric cable sheathing, and type metals for printing presses, which apparently are not completely extinct yet. It's also used in flame retardants, and - this is key - in semiconductors. It's also has applications in pharmaceuticals. a key strategic mineral. Alaska has antimony. Now, in Alaska, a company called Nova Minerals, with a grant from the War Department, has a contract to build an antimony refinery at Port MacKenzie, west of Anchorage, to process ore from the Estelle gold mine in the West Susitna Mineral District. With Pentagon backing and a goal to begin delivering Alaska-sourced antimony into U.S. supply chains by 2027, Nova Minerals Ltd. has secured a 42.8-acre site at Port MacKenzie west of Anchorage for a refinery that would process antimony concentrates from its Estelle project and other sources."This is a defining moment for Nova Minerals and for U.S. critical mineral independence," Nova Minerals CEO Christopher Gerteisen said upon securing land use permits for the industrial site about four miles from a deepwater port in Southcentral Alaska.The refinery, to be developed by Nova subsidiary Alaska Range Resources (ARR), is part of a strategy to leverage the very high-grade antimony mineralization found on the company's Estelle project about 100 miles west of Port MacKenzie to establish a domestic supply of this metalloid critical to a wide range of military and commercial applications. Antimony is also found in Idaho and Montana. But a majority of antimony production comes from countries that are not particularly friendly to the United States: China, Russia, and Tajikistan, which, between them, account for almost 80 percent of global supply. Source: redstate.com Johnson Warns Current Government Shutdown Could Be Longest Ever House Speaker Mike Johnson (R-La.) said on Oct.
Send us a textAaron takes the mic solo and unloads on pipeline myths, training excuses, and bad packet habits. Forget the rumor mill—he explains why the Air Force keeps tweaking Special Warfare selection, why “pipeline optimization” isn't a conspiracy, and why faster runners are always the ones who graduate. He drags combat controllers over pistol skills, laughs about swim cap questions, and gives the blunt truth: stop wasting time and train specifically for what actually matters. It's snarky, savage, and brutally useful—classic Aaron, unfiltered.⏱️ Timestamps00:00 – Intro chaos and tech fail shoutout 02:05 – Pipeline rumors: water vs land 04:15 – Why change is constant in selection 08:55 – Pipeline optimization explained (no more wasted time) 11:05 – The real mission: why operators exist 15:40 – Selling the new pipeline in one sentence 17:50 – The Zulu Course: common skills, common pain 19:25 – Combat controller pistol roast 21:40 – What you should actually train for 23:55 – Why fast runners always win 28:40 – Pull-up standards and the Pose Fitness app 33:05 – Grip strength is king 35:20 – Swim efficiency and wall push-offs 39:50 – Stowe Phase I vs Phase II: packet perfection 44:30 – What Phase II really feels like 46:45 – Officers, packets, and dumb mistakes 49:05 – Who actually camps more: PJ, CCT, or SR? 55:35 – Underwaters in OCPs: why it sucks and how to prep 57:55 – Could the Air Force run its own schools? Nope
In this episode, we review the high-yield topic of Phase I vs. Phase II Metabolism from the Pharmacology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
This week Dan Morehead joins the show to discuss the current state of markets & what's next throughout 2025 into 2026. We deep dive into how Dan built conviction in crypto as an asset class back in 2013, does the four year cycle still exist, crypto treasury vehicles, Dan's Solana thesis & more. Enjoy! -- Follow Dan: https://x.com/dan_pantera Follow Jason: https://x.com/JasonYanowitz Follow Empire: https://twitter.com/theempirepod -- Join the Empire Telegram: https://t.me/+CaCYvTOB4Eg1OWJh Start your day with crypto news, analysis and data from David Canellis. Subscribe to the Empire newsletter: https://blockworks.co/newsletter/empire?utm_source=podcasts -- Crypto-native institutions and developers demand institutional-grade infrastructure with regulatory clarity and full asset control. Blockdaemon's Earn Stack is a non-custodial platform combining high-performance staking rewards and seamless DeFi integration with no intermediate smart contract or vaults. Programmatically access leading Ethereum & Solana staking rewards, plus DeFi opportunities across lending protocols, DEXs, and AMMs. Book a Demo! -- Welcome to Get Real — Web3's first-ever campaign rewarding you for creating real-world value. Connect your devices to real-world apps on peaq and earn rewards for: Measuring noise pollution Providing compute Mapping the word And more Total prize pool: 5% of $PEAQ's initial supply. Get Real is relaunching soon — follow peaq on X and get ready. -- Mantle is pioneering ""Blockchain for Banking"" as a revolutionary new category that sits at the intersection of TradFi and web3. Key elements for Mantle as the ""Blockchain for Banking"": - Transactions posted to the blockchain - Compatibility with TradFi rails - Integrated DeFi features Mantle Network, the access layer — transforms Mantle Network into a purpose-built vertical platform — the blockchain for banking — that enables financial services on-chain. Mantle leads the establishment of Blockchain for Banking as the next frontier. Follow Mantle on X (@Mantle_Official) for the latest updates on Mantle as the 'Blockchain for Banking'. -- GEODNET is the world's largest RTK network, delivering real-time, centimeter-level precision for drones, robots, farmers, and first responders. Recognized by the U.S. Congress, this blockchain-powered network supports mission-critical applications across a wide range of industries. Discover how GEODNET is changing the world: [https://geodnet.com] -- Timestamps: (00:00) Introduction (02:44) Buying Bitcoin In The Early Days (07:11) Dan's Macro Outlook In 2025 (17:14) Ads (Blockdaemon, Peaq) (18:44) Does The Four Year Cycle Still Exist? (27:39) Phase II of The Bull Market (29:49) The Crypto IPO Window Is Open (32:44) Ads (Blockdaemon, Peaq) (34:13) Crypto Treasury Vehicles (40:30) The Solana Thesis: Why Pantera Owns $1bn+ Solana (42:45) Are Institutions Still Underallocated To Crypto? (46:33) Ads (Manttle, Goednet) (47:59) Launching Crypto's Longest Running Fund (55:07) Advice For Founders (57:50) Crypto's Biggest Opportunity In The Next 5 Years -- Disclaimer: Nothing said on Empire is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Santiago, Jason, and our guests may hold positions in the companies, funds, or projects discussed.
Ethan is a Baltimore-area investor who moved from offices and strip centers into strictly industrial after years of high capex and constant turnover in those assets. His 30,000 sf small-bay warehouse bought in 2013 for $2.15M has run nearly full for 12 years, needed little capex, and is now worth about $4.5M. Limited new supply of small bay, 3 percent annual rent bumps, and sticky tenants made it a cash cow. He sees big funds drifting down-market from big box to chase yield, but notes small-bay tenants are gritty and practical, so local owners who know the profile often have an edge.He has doubled down on industrial outdoor storage. A 16-acre site near Dover was bought for about $1.2M, improved with gravel, fencing, solar lights, cameras and an app-controlled gate, then run by a truck-parking operator. Pricing is about $175 per spot per month with daily and weekly options, modeled for roughly 180 stalls and now about 65 percent occupied, already covering the mortgage. He financed quickly via a line of credit then plans to refi after stabilization. A failed Phase I led to a clean Phase II, which unlocked the deal. He also owns two 5,000 sf warehouses with 1.5 acre yards leased to a pipe distributor, a contractor and a granite company, plus another IOS site across from Dover being turned into containerized self-storage. Strategy wise he avoids Baltimore City's higher taxes, favors Harford County and secondary markets near highways on the I-95 corridor, and targets IOS parcels of 3 to 5 acres or more where supply is scarce and demand is deep.--
We’re concluding our read of Zoraida Cordova’s novel, Convergence, part of Phase II of the High Republic project. This time, we talk about hoarding weapons of mass destruction, trusting your instincts, and real-world pop culture nods in the GFFA. For a list of Black-owned bookstores to order from, now and always, click here. You can […]
We weigh in on the recent DoJ Epstein memo and tape. Plus: Elon and Hitler. Hit the tip line: (646) 801-1129 | tips@trueanon.com Discover more episodes at podcast.trueanon.com
© 2020-2026 Ivy Podcast Discovery LLC
